HYL fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
HYL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company